Futura Medical
is the developer of innovative sexual health products, including lead product Eroxon®. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Our purpose is to provide a range of clinically proven sexual health products that enhance quality of life.
Share Price
Eroxon®
Eroxon® is a breakthrough treatment for erectile dysfunction and is the only fast-acting topical clinically proven treatment for erectile dysfunction available without prescription in Europe and in the USA.
Eroxon® is clinically proven to help men achieve an erection within 10 minutes and is authorized by the FDA.
Eroxon® is approved in a number of markets across the world including in Europe and the USA. Eroxon® launched in its first markets the UK and Belgium in 2023, being available to consumers for the first time and changing the lives of men with ED and their partners. Eroxon® is now available to purchase in over 15 countries worldwide including the USA, Mexico, throughout most of Europe and a number of countries in the Middle East.
Our Products
Futura Medical specialises in the development and global commercialisation of innovative and proprietary sexual health products. Our lead product is Eroxon®, a clinically proven breakthrough treatment for erectile dysfunction and we have two products in our development pipeline Eroxon® Intense, a product extension for men who want a stronger sensation than that provided by Eroxon® and WSD4000 a treatment for the symptoms associated with sexual dysfunction in women. We are experts in the research, development and commercialisation of topically delivered gel formulations to improve sexual health.
Business Model
Futura’s business model focuses on a de-risked go-to-market strategy via leading consumer healthcare partners who are well resourced to commit significant marketing spend and expertise. Futura has distribution partners in place for Eroxon® in a number of major consumer markets including Haleon plc in the USA, the largest consumer health market in the world, and Cooper Consumer Health in Europe.
Investor Centre
Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Our Strategy
Our strategy is to develop and commercialise innovative and clinically proven products for the OTC sexual health market. Our de-risked go-to-market strategy is to partner with leading consumer healthcare partners who are well resourced to commit significant marketing spend and expertise to engage effectively with consumers.